PolyPid to Report Third Quarter 2021 Financial Results and Operational Highlights on November 10, 2021

Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) will report its third quarter 2021 financial results and operational highlights on November 10, 2021, before U.S. markets open. The company is focused on developing therapeutics using its PLEX technology, currently advancing its lead candidate D-PLEX100 through Phase 3 clinical trials aimed at preventing surgical site infections. A conference call and webcast will take place at 8:30 AM ET on the same day to discuss results and updates.

Positive

• Company is advancing D-PLEX100 in Phase 3 clinical trials.
• Focus on improving surgical outcomes with PLEX technology.

Negative

• None.

PETAH TIKVA, Israel, Nov. 01, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report its third quarter 2021 financial results and operational highlights before the open of the U.S. stock markets on Wednesday, November 10, 2021. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:

Date:	Wednesday, November 10, 2021
Time:	8:30 AM Eastern Time
United States:	+1 877 870 9135
Israel:	+972 1809 213-985
International:	+44 (0) 2071 928338
Conference ID:	4585862
Webcast:	https://edge.media-server.com/mmc/p/5rbkqsbe

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a phase 3 biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics. PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with medications, enables precise delivery of drugs at effective release rates, over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trials for the prevention of sternal and abdominal surgical site infections (SSIs).

For additional company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

Contacts: 
PolyPid, Ltd. 
Dikla Czaczkes Akselbrad
EVP & CFO
Tel: +972-747195700

Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com

FAQ

When will PolyPid report its third quarter 2021 financial results?

PolyPid will report its third quarter 2021 financial results on November 10, 2021.

What is the main product candidate of PolyPid?

PolyPid's main product candidate is D-PLEX100, which is in Phase 3 clinical trials for preventing surgical site infections.

What time is the PolyPid conference call on November 10, 2021?

The PolyPid conference call will begin at 8:30 AM Eastern Time on November 10, 2021.

What technology does PolyPid use in its therapeutics?

PolyPid uses its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology for drug delivery.

Where can I find more information about PolyPid?

More information about PolyPid can be found on their official website at www.polypid.com.